Last week, Allergan's CEO told investors that Botox “continues to remain very strong” in migraine despite the arrival of three new CGRP drugs. But how…

In a first for pharma and healthcare agencies, McCann Health has hired a global creative chief directly from a large consumer agency.

Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.

Investors had been worried that growth for Regeneron’s Eylea was slowing down, but Monday the company batted away those fears.

Alexion aims to transform from an ultrarare-disease company to a rare-disease company—and to make that happen, its pricing has to change.

With key commercial cog Mark Mallon bound for Ironwood’s CEO spot, AstraZeneca is reorganizing into two new R&D and commercial lineups.

Matt Eastwood, McCann Health’s new global chief creative officer, fills a role that's been vacant since July.

The Philadelphia city council paused its proposal to regulate pharmaceutical sales reps at the final meeting of the year but will take it up in 2019.